About takeda pharmaceutical co. ltd. - TAK
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following business divisions: Gastrointestinal Diseases, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
TAK At a Glance
Takeda Pharmaceutical Co., Ltd.
2-1-1 Nihonbashi-Honcho
Osaka, Osaka 103-8668
| Phone | 81-3-3278-2111 | Revenue | 29.90B | |
| Industry | Pharmaceuticals: Major | Net Income | -1,011,260,810.80 | |
| Sector | Health Technology | Employees | 47,029 | |
| Fiscal Year-end | 03 / 2027 | |||
| View SEC Filings |
TAK Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.951 |
| Price to Book Ratio | 1.253 |
| Price to Cash Flow Ratio | 9.37 |
| Enterprise Value to EBITDA | 9.903 |
| Enterprise Value to Sales | 2.978 |
| Total Debt to Enterprise Value | 0.387 |
TAK Efficiency
| Revenue/Employee | 635,781.686 |
| Income Per Employee | -21,502.92 |
| Receivables Turnover | 5.428 |
| Total Asset Turnover | 0.31 |
TAK Liquidity
| Current Ratio | 1.091 |
| Quick Ratio | 0.598 |
| Cash Ratio | 0.21 |
TAK Profitability
| Gross Margin | 54.095 |
| Operating Margin | 14.063 |
| Pretax Margin | -3.111 |
| Net Margin | -3.382 |
| Return on Assets | -1.049 |
| Return on Equity | -2.173 |
| Return on Total Capital | -1.247 |
| Return on Invested Capital | -1.315 |
TAK Capital Structure
| Total Debt to Total Equity | 73.712 |
| Total Debt to Total Capital | 42.433 |
| Total Debt to Total Assets | 35.305 |
| Long-Term Debt to Equity | 65.937 |
| Long-Term Debt to Total Capital | 37.958 |